Sector ratings Alnylam Pharmaceuticals, Inc.

Equities

Market Closed - Nasdaq Other stock markets 21:00:00 16/04/2026 BST			5-day change	1st Jan Change
320.13 ^USD	-3.98%		-0.36%	-19.49%

04-06	BioCryst Pharmaceuticals, Inc. Appoints Sandeep M. Menon As Chief Research And Development Officer	CI
03-30	Alnylam Pharmaceuticals Announces New Data Supporting Benefits of Vutrisiran in Attr-Cm and Potential of Zilebesiran for Hypertension Management	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Capi.($)	Investor	ESG MSCI	Fundamentals	Financial revisions	Global Valuation	Visibility	Consensus
ALNYLAM PHARMACEUTICALS, INC.	42.46B		AA
ELI LILLY AND COMPANY	809B		A
JOHNSON & JOHNSON	565B		BBB
ABBVIE INC.	370B		AA
ROCHE HOLDING AG	320B		AA			-		-
ASTRAZENECA PLC	312B		A
MERCK & CO., INC.	285B		A
NOVARTIS AG	286B		AAA
AMGEN INC.	189B		A
NOVO NORDISK A/S	180B		A
GILEAD SCIENCES, INC.	172B		AA
PFIZER INC.	155B		A
BRISTOL-MYERS SQUIBB COMPANY	120B		A
SANOFI	115B		AA
GSK PLC	115B		AA
VERTEX PHARMACEUTICALS INCORPORATED	111B		AA
CHUGAI PHARMACEUTICAL CO., LTD.	88.83B		AA
ALLERGAN PLC	63.66B	-	-	-	-	-	-	-
TAKEDA PHARMACEUTICAL COMPANY LIMITED	56.04B		AA
JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD	55.87B		AA
Average	220.45B		AA
Weighted average by Cap.			AA